On the stock market since 2013, it operates in the world of health and science. It has 357 employees. Now — the numbers.
This is an established company with proven profits.
No real growth (-2% a year).
The gap is $74.9M. In times of high interest rates, a gap like that can squeeze a company.
Executives buying with their own money is usually read as confidence in the company’s future.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
Growth: Sales growth trails the sector average.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
The stock trades 59% below its peak. The market has trimmed its expectations for the company.
Over the last 12 months, company executives reported 17 buys and 4 sells. Management buying with its own money is usually read as a good sign.
It pays out $0.60 per share each year — regular cash for whoever holds the stock.
Over the last 3 years, sales fell about 3% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
The company’s market value is 40 times its annual profit. Even a small disappointment could hit the price hard.
On our five-subject report card, NRC sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: NRC is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.